National Guideline Clearinghouse | Screening for depression in children and adolescents: U.S. Preventive Services Task Force recommendation statement.

National Guideline Clearinghouse | Screening for depression in children and adolescents: U.S. Preventive Services Task Force recommendation statement.

U.S. Preventive Services Task Force

• Screening for depression in children and adolescents: U.S. Preventive Services Task Force recommendation statement. This updates a previously published guideline summary.

Guideline Title Screening for depression in children and adolescents: U.S. Preventive Services Task Force recommendation statement. Bibliographic Source(s) U.S. Preventive Services Task Force. Screening for depression in children and adolescents: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016 Mar 1;164(5):360-6. [20 references] PubMed  Guideline Status This is the current release of the guideline. This guideline updates a previous version: U.S. Preventive Services Task Force. Screening and treatment for major depressive disorder in children and adolescents. Pediatrics 2009;123:1223-1228. [6 references] This guideline meets NGC's 2013 (revised) inclusion criteria.

---------

Screening for Depression in Children and Adolescents: U.S. Preventive Services Task Force Recommendation Statement. - PubMed - NCBI

Ann Intern Med. 2016 Mar 1;164(5):360-6. doi: 10.7326/M15-2957. Epub 2016 Feb 9.

Screening for Depression in Children and Adolescents: U.S. Preventive Services Task Force Recommendation Statement.

Siu AL; U.S. Preventive Services Task Force.

Abstract

DESCRIPTION:

Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents.

METHODS:

The USPSTF reviewed the evidence on the benefits and harms of screening; the accuracy of primary care-feasible screening tests; and the benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years.

POPULATION:

This recommendation applies to children and adolescents aged 18 years or younger who do not have a diagnosis of MDD.

RECOMMENDATION:

The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged 11 years or younger. (I statement).

PMID:

 

26858097

 

[PubMed - in process]